{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:37Z","timestamp":1787020237773,"version":"build-2736575974"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancers, is driven by oncogenic KRAS mutations. Farnesyl thiosalicylic acid (FTS), also known as salirasib, is a RAS inhibitor that selectively dislodges active RAS proteins from cell membrane, inhibiting downstream signaling. FTS has demonstrated limited therapeutic efficacy in PDAC patients despite being well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To improve the efficacy of FTS in PDAC, we performed a genome-wide CRISPR synthetic lethality screen to identify genetic targets that synergize with FTS treatment. Among the top candidates, multiple genes in the endoplasmic reticulum-associated protein degradation (ERAD) pathway were identified. The role of ERAD inhibition in enhancing the therapeutic efficacy of FTS was further investigated in pancreatic cancer cells using pharmaceutical and genetic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In murine and human PDAC cells, FTS induced unfolded protein response (UPR), which was further augmented upon treatment with a chemical inhibitor of ERAD, Eeyarestatin I (EerI). Combined treatment with FTS and EerI significantly upregulated the expression of UPR marker genes and induced apoptosis in pancreatic cancer cells. Furthermore, CRISPR-based genetic ablation of the key ERAD components, HRD1 and SEL1L, sensitized PDAC cells to FTS treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study reveals a critical role for ERAD in therapeutic response of FTS and points to the modulation of UPR as a novel approach to improve the efficacy of FTS in PDAC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-07967-6","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T14:03:57Z","timestamp":1615039437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells"],"prefix":"10.1186","volume":"21","author":[{"given":"Rong","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delaney K.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy G.","family":"Azizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"issue":"10039","key":"7967_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73\u201385.","journal-title":"Lancet"},{"key":"7967_CR2","doi-asserted-by":"crossref","unstructured":"Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018;8(9):a031435.","DOI":"10.1101\/cshperspect.a031435"},{"issue":"5","key":"7967_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","volume":"129","author":"JL Bos","year":"2007","unstructured":"Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell. 2007;129(5):865\u201377.","journal-title":"Cell"},{"issue":"11","key":"7967_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"7967_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc2960","volume":"10","author":"D Vigil","year":"2010","unstructured":"Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010;10(12):842\u201357.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"7967_CR6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13(11):828\u201351.","journal-title":"Nat Rev Drug Discov"},{"issue":"31","key":"7967_CR7","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1200\/JCO.2015.62.1052","volume":"33","author":"H Singh","year":"2015","unstructured":"Singh H, Longo DL, Chabner BA. Improving prospects for targeting RAS. J Clin Oncol. 2015;33(31):3650\u20139.","journal-title":"J Clin Oncol"},{"key":"7967_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2018.01.017","volume":"54","author":"NI Mar\u00edn-Ramos","year":"2019","unstructured":"Mar\u00edn-Ramos NI, Ortega-Guti\u00e9rrez S, L\u00f3pez-Rodr\u00edguez ML. Blocking Ras inhibition as an antitumor strategy. Semin Cancer Biol. 2019;54:91\u2013100.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"7967_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","volume":"25","author":"AG Stephen","year":"2014","unstructured":"Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell. 2014;25(3):272\u201381.","journal-title":"Cancer Cell"},{"issue":"7477","key":"7967_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548\u201351.","journal-title":"Nature"},{"issue":"1","key":"7967_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/anie.201307387","volume":"53","author":"SM Lim","year":"2014","unstructured":"Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Eng. 2014;53(1):199\u2013204.","journal-title":"Angew Chem Int Ed Eng"},{"issue":"6273","key":"7967_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.aad6204","volume":"351","author":"P Lito","year":"2016","unstructured":"Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351(6273):604\u20138.","journal-title":"Science"},{"issue":"3","key":"7967_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018;172(3):578\u2013589.e517.","journal-title":"Cell"},{"issue":"7781","key":"7967_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217\u201323.","journal-title":"Nature"},{"key":"7967_CR15","doi-asserted-by":"crossref","unstructured":"Ahearn I, Zhou M, Philips MR. Posttranslational Modifications of RAS Proteins. Cold Spring Harb Perspect Med. 2018;8(11):a031484.","DOI":"10.1101\/cshperspect.a031484"},{"issue":"2","key":"7967_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrm.2015.11","volume":"17","author":"M Wang","year":"2016","unstructured":"Wang M, Casey PJ. Protein prenylation: unique fats make their mark on biology. Nat Rev Mol Cell Biol. 2016;17(2):110\u201322.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"38","key":"7967_CR17","doi-asserted-by":"publisher","first-page":"22263","DOI":"10.1074\/jbc.270.38.22263","volume":"270","author":"M Marom","year":"1995","unstructured":"Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem. 1995;270(38):22263\u201370.","journal-title":"J Biol Chem"},{"key":"7967_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0076-6879(07)00432-6","volume":"439","author":"B Rotblat","year":"2008","unstructured":"Rotblat B, Ehrlich M, Haklai R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467\u201389.","journal-title":"Methods Enzymol"},{"issue":"6","key":"7967_CR19","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-06-0706","volume":"6","author":"A Zundelevich","year":"2007","unstructured":"Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther. 2007;6(6):1765\u201373.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"7967_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00280-007-0451-6","volume":"61","author":"R Haklai","year":"2008","unstructured":"Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol. 2008;61(1):89\u201396.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"7967_CR21","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/JTO.0b013e318223c099","volume":"6","author":"GJ Riely","year":"2011","unstructured":"Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, et al. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol. 2011;6(8):1435\u20137.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"7967_CR22","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s10637-012-9818-6","volume":"30","author":"D Laheru","year":"2012","unstructured":"Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, et al. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer. Investig New Drugs. 2012;30(6):2391\u20139.","journal-title":"Investig New Drugs"},{"issue":"7","key":"7967_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clml.2015.02.018","volume":"15","author":"T Badar","year":"2015","unstructured":"Badar T, Cortes JE, Ravandi F, O'Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015;15(7):433\u2013438.e432.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7524","key":"7967_CR24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nature13611","volume":"514","author":"A Viale","year":"2014","unstructured":"Viale A, Pettazzoni P, Lyssiotis CA, Ying H, S\u00e1nchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514(7524):628\u201332.","journal-title":"Nature"},{"issue":"4","key":"7967_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","volume":"25","author":"KL Bryant","year":"2019","unstructured":"Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019;25(4):628\u201340.","journal-title":"Nat Med"},{"issue":"9","key":"7967_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin Jr","year":"2005","unstructured":"Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689\u201398.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7967_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-020-00956-5","volume":"13","author":"W Topatana","year":"2020","unstructured":"Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J, Suliyanto K, Ma D, Zhang B, Chen M, et al. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol. 2020;13(1):118.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"7967_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, Majeti R. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178\u201384.","journal-title":"Nat Med"},{"issue":"5","key":"7967_CR29","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jhep.2018.07.004","volume":"69","author":"C Wang","year":"2018","unstructured":"Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, Xue Z, Wang L, Beijersbergen RL, Qin W, et al. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol. 2018;69(5):1057\u201365.","journal-title":"J Hepatol"},{"issue":"6166","key":"7967_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84\u20137.","journal-title":"Science"},{"issue":"6","key":"7967_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.3536","volume":"34","author":"B Evers","year":"2016","unstructured":"Evers B, Jastrzebski K, Heijmans JP, Grernrum W, Beijersbergen RL, Bernards R. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat Biotechnol. 2016;34(6):631\u20133.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"7967_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI59227","volume":"122","author":"MA Collins","year":"2012","unstructured":"Collins MA, Bednar F, Zhang Y, Brisset JC, Galb\u00e1n S, Galb\u00e1n CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest. 2012;122(2):639\u201353.","journal-title":"J Clin Invest"},{"issue":"12","key":"7967_CR33","doi-asserted-by":"publisher","first-page":"e49707","DOI":"10.1371\/journal.pone.0049707","volume":"7","author":"MA Collins","year":"2012","unstructured":"Collins MA, Brisset JC, Zhang Y, Bednar F, Pierre J, Heist KA, Galb\u00e1n CJ, Galb\u00e1n S, di Magliano MP. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One. 2012;7(12):e49707.","journal-title":"PLoS One"},{"issue":"4","key":"7967_CR34","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE, Zhang F. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12(4):828\u201363.","journal-title":"Nat Protoc"},{"issue":"W1","key":"7967_CR35","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"7967_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-019-0803-9","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu Y, Azizian NG, Dou Y, Pham LV, Li Y. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J Hematol Oncol. 2019;12(1):119.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"7967_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34(2):184\u201391.","journal-title":"Nat Biotechnol"},{"key":"7967_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13059-015-0843-6","volume":"16","author":"W Li","year":"2015","unstructured":"Li W, K\u00f6ster J, Xu H, Chen CH, Xiao T, Liu JS, Brown M, Liu XS. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 2015;16:281.","journal-title":"Genome Biol"},{"issue":"1","key":"7967_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ncb2383","volume":"14","author":"JC Christianson","year":"2011","unstructured":"Christianson JC, Olzmann JA, Shaler TA, Sowa ME, Bennett EJ, Richter CM, Tyler RE, Greenblatt EJ, Harper JW, Kopito RR. Defining human ERAD networks through an integrative mapping strategy. Nat Cell Biol. 2011;14(1):93\u2013105.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"7967_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.molcel.2018.11.015","volume":"73","author":"DE Leto","year":"2019","unstructured":"Leto DE, Morgens DW, Zhang L, Walczak CP, Elias JE, Bassik MC, Kopito RR. Genome-wide CRISPR Analysis Identifies Substrate-Specific Conjugation Modules in ER-Associated Degradation. Mol Cell. 2019;73(2):377\u2013389.e311.","journal-title":"Mol Cell"},{"key":"7967_CR41","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1146\/annurev-biochem-062917-012749","volume":"87","author":"N Berner","year":"2018","unstructured":"Berner N, Reutter KR, Wolf DH. Protein quality control of the endoplasmic reticulum and ubiquitin-proteasome-triggered degradation of aberrant proteins: yeast pioneers the path. Annu Rev Biochem. 2018;87:751\u201382.","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"7967_CR42","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1074\/jbc.M307453200","volume":"279","author":"M Kikkert","year":"2004","unstructured":"Kikkert M, Doolman R, Dai M, Avner R, Hassink G, van Voorden S, Thanedar S, Roitelman J, Chau V, Wiertz E. Human HRD1 is an E3 ubiquitin ligase involved in degradation of proteins from the endoplasmic reticulum. J Biol Chem. 2004;279(5):3525\u201334.","journal-title":"J Biol Chem"},{"issue":"3","key":"7967_CR43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41556-020-0473-4","volume":"22","author":"V Vasic","year":"2020","unstructured":"Vasic V, Denkert N, Schmidt CC, Riedel D, Stein A, Meinecke M. Hrd1 forms the retrotranslocation pore regulated by auto-ubiquitination and binding of misfolded proteins. Nat Cell Biol. 2020;22(3):274\u201381.","journal-title":"Nat Cell Biol"},{"issue":"35","key":"7967_CR44","doi-asserted-by":"publisher","first-page":"25330","DOI":"10.1074\/jbc.M113.455212","volume":"288","author":"CH Huang","year":"2013","unstructured":"Huang CH, Hsiao HT, Chu YR, Ye Y, Chen X. Derlin2 protein facilitates HRD1-mediated retro-translocation of sonic hedgehog at the endoplasmic reticulum. J Biol Chem. 2013;288(35):25330\u20139.","journal-title":"J Biol Chem"},{"issue":"43","key":"7967_CR45","doi-asserted-by":"publisher","first-page":"37602","DOI":"10.1074\/jbc.M111.284794","volume":"286","author":"EJ Klemm","year":"2011","unstructured":"Klemm EJ, Spooner E, Ploegh HL. Dual role of ancient ubiquitous protein 1 (AUP1) in lipid droplet accumulation and endoplasmic reticulum (ER) protein quality control. J Biol Chem. 2011;286(43):37602\u201314.","journal-title":"J Biol Chem"},{"issue":"6","key":"7967_CR46","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tcb.2016.12.002","volume":"27","author":"L Qi","year":"2017","unstructured":"Qi L, Tsai B, Arvan P. New insights into the physiological role of endoplasmic reticulum-associated degradation. Trends Cell Biol. 2017;27(6):430\u201340.","journal-title":"Trends Cell Biol"},{"key":"7967_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ceb.2018.04.004","volume":"53","author":"X Wu","year":"2018","unstructured":"Wu X, Rapoport TA. Mechanistic insights into ER-associated protein degradation. Curr Opin Cell Biol. 2018;53:22\u20138.","journal-title":"Curr Opin Cell Biol"},{"issue":"15","key":"7967_CR48","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1007\/s00018-008-8072-8","volume":"65","author":"C Schuberth","year":"2008","unstructured":"Schuberth C, Buchberger A. UBX domain proteins: major regulators of the AAA ATPase Cdc48\/p97. Cell Mol Life Sci. 2008;65(15):2360\u201371.","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"7967_CR49","doi-asserted-by":"publisher","first-page":"7445","DOI":"10.1074\/jbc.M708347200","volume":"283","author":"Q Wang","year":"2008","unstructured":"Wang Q, Li L, Ye Y. Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem. 2008;283(12):7445\u201354.","journal-title":"J Biol Chem"},{"issue":"11","key":"7967_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015479","volume":"5","author":"Q Wang","year":"2010","unstructured":"Wang Q, Shinkre BA, Lee JG, Weniger MA, Liu Y, Chen W, Wiestner A, Trenkle WC, Ye Y. The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97\/VCP inhibitory group. PLoS One. 2010;5(11):e15479.","journal-title":"PLoS One"},{"key":"7967_CR51","doi-asserted-by":"publisher","first-page":"15047","DOI":"10.1038\/cddiscovery.2015.47","volume":"1","author":"A Menachem","year":"2015","unstructured":"Menachem A, Bodner O, Pastor J, Raz A, Kloog Y. Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors. Cell Death Dis. 2015;1:15047.","journal-title":"Cell Death Dis"},{"key":"7967_CR52","doi-asserted-by":"crossref","unstructured":"Karag\u00f6z GE, Acosta-Alvear D, Walter P. The Unfolded Protein Response: Detecting and Responding to Fluctuations in the Protein-Folding Capacity of the Endoplasmic Reticulum. Cold Spring Harb Perspect Biol. 2019;11(9):a033886.","DOI":"10.1101\/cshperspect.a033886"},{"issue":"8","key":"7967_CR53","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.tibs.2018.06.005","volume":"43","author":"J Hwang","year":"2018","unstructured":"Hwang J, Qi L. Quality control in the endoplasmic reticulum: crosstalk between ERAD and UPR pathways. Trends Biochem Sci. 2018;43(8):593\u2013605.","journal-title":"Trends Biochem Sci"},{"issue":"10","key":"7967_CR54","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/ijc.25102","volume":"126","author":"S Yaari-Stark","year":"2010","unstructured":"Yaari-Stark S, Shaked M, Nevo-Caspi Y, Jacob-Hircsh J, Shamir R, Rechavi G, Kloog Y. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. Int J Cancer. 2010;126(10):2268\u201381.","journal-title":"Int J Cancer"},{"issue":"7","key":"7967_CR55","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1158\/0008-5472.CAN-06-4287","volume":"67","author":"R Blum","year":"2007","unstructured":"Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res. 2007;67(7):3320\u20138.","journal-title":"Cancer Res"},{"issue":"7","key":"7967_CR56","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1073\/pnas.0807611106","volume":"106","author":"Q Wang","year":"2009","unstructured":"Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T, Ron D, Chen W, Trenkle W, Wiestner A, et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A. 2009;106(7):2200\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 23","key":"7967_CR57","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1242\/jcs.054494","volume":"122","author":"BC Cross","year":"2009","unstructured":"Cross BC, McKibbin C, Callan AC, Roboti P, Piacenti M, Rabu C, Wilson CM, Whitehead R, Flitsch SL, Pool MR, et al. Eeyarestatin I inhibits Sec61-mediated protein translocation at the endoplasmic reticulum. J Cell Sci. 2009;122(Pt 23):4393\u2013400.","journal-title":"J Cell Sci"},{"issue":"7","key":"7967_CR58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm2199","volume":"8","author":"D Ron","year":"2007","unstructured":"Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519\u201329.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"7967_CR59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ncb2738","volume":"15","author":"J Han","year":"2013","unstructured":"Han J, Back SH, Hur J, Lin YH, Gildersleeve R, Shan J, Yuan CL, Krokowski D, Wang S, Hatzoglou M, et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol. 2013;15(5):481\u201390.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"7967_CR60","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.molcel.2017.06.017","volume":"69","author":"C Hetz","year":"2018","unstructured":"Hetz C, Papa FR. The unfolded protein response and cell fate control. Mol Cell. 2018;69(2):169\u201381.","journal-title":"Mol Cell"},{"issue":"2","key":"7967_CR61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/febs.14608","volume":"286","author":"A Almanza","year":"2019","unstructured":"Almanza A, Carlesso A, Chintha C, Creedican S, Doultsinos D, Leuzzi B, Lu\u00eds A, McCarthy N, Montibeller L, More S, et al. Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications. FEBS J. 2019;286(2):241\u201378.","journal-title":"FEBS J"},{"issue":"5","key":"7967_CR62","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.trecan.2016.03.007","volume":"2","author":"H Urra","year":"2016","unstructured":"Urra H, Dufey E, Avril T, Chevet E, Hetz C. Endoplasmic reticulum stress and the hallmarks of Cancer. Trends Cancer. 2016;2(5):252\u201362.","journal-title":"Trends Cancer"},{"issue":"4","key":"7967_CR63","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.cell.2016.12.004","volume":"168","author":"JR Cubillos-Ruiz","year":"2017","unstructured":"Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in Cancer. Cell. 2017;168(4):692\u2013706.","journal-title":"Cell"},{"issue":"5","key":"7967_CR64","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.ajpath.2020.01.010","volume":"190","author":"SA Oakes","year":"2020","unstructured":"Oakes SA. Endoplasmic reticulum stress signaling in Cancer cells. Am J Pathol. 2020;190(5):934\u201346.","journal-title":"Am J Pathol"},{"issue":"2","key":"7967_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm3270","volume":"13","author":"C Hetz","year":"2012","unstructured":"Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2):89\u2013102.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"7967_CR66","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1016\/j.bbamcr.2013.07.024","volume":"1833","author":"H Urra","year":"2013","unstructured":"Urra H, Dufey E, Lisbona F, Rojas-Rivera D, Hetz C. When ER stress reaches a dead end. Biochim Biophys Acta. 2013;1833(12):3507\u201317.","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"7967_CR67","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1016\/j.bbamcr.2013.06.028","volume":"1833","author":"R Sano","year":"2013","unstructured":"Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833(12):3460\u201370.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"7967_CR68","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/ncb0311-184","volume":"13","author":"I Tabas","year":"2011","unstructured":"Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011;13(3):184\u201390.","journal-title":"Nat Cell Biol"},{"issue":"14","key":"7967_CR69","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1111\/febs.13598","volume":"283","author":"R Iurlaro","year":"2016","unstructured":"Iurlaro R, Mu\u00f1oz-Pinedo C. Cell death induced by endoplasmic reticulum stress. FEBS J. 2016;283(14):2640\u201352.","journal-title":"FEBS J"},{"issue":"4","key":"7967_CR70","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1128\/MCB.21.4.1249-1259.2001","volume":"21","author":"KD McCullough","year":"2001","unstructured":"McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol. 2001;21(4):1249\u201359.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"7967_CR71","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.cdd.4401373","volume":"11","author":"S Oyadomari","year":"2004","unstructured":"Oyadomari S, Mori M. Roles of CHOP\/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004;11(4):381\u20139.","journal-title":"Cell Death Differ"},{"issue":"6","key":"7967_CR72","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1083\/jcb.200904060","volume":"186","author":"G Li","year":"2009","unstructured":"Li G, Mongillo M, Chin KT, Harding H, Ron D, Marks AR, Tabas I. Role of ERO1-alpha-mediated stimulation of inositol 1,4,5-triphosphate receptor activity in endoplasmic reticulum stress-induced apoptosis. J Cell Biol. 2009;186(6):783\u201392.","journal-title":"J Cell Biol"},{"issue":"7","key":"7967_CR73","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.cell.2007.04.027","volume":"129","author":"H Puthalakath","year":"2007","unstructured":"Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-Breschkin J, Motoyama N, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007;129(7):1337\u201349.","journal-title":"Cell"},{"issue":"24","key":"7967_CR74","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1101\/gad.1250704","volume":"18","author":"SJ Marciniak","year":"2004","unstructured":"Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, Nagata K, Harding HP, Ron D. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 2004;18(24):3066\u201377.","journal-title":"Genes Dev"},{"issue":"44","key":"7967_CR75","doi-asserted-by":"publisher","first-page":"45495","DOI":"10.1074\/jbc.M406933200","volume":"279","author":"H Yamaguchi","year":"2004","unstructured":"Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 2004;279(44):45495\u2013502.","journal-title":"J Biol Chem"},{"issue":"6","key":"7967_CR76","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/sj.emboj.7600596","volume":"24","author":"N Ohoka","year":"2005","unstructured":"Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J. 2005;24(6):1243\u201355.","journal-title":"EMBO J"},{"issue":"9","key":"7967_CR77","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/cdd.2017.82","volume":"24","author":"P Pih\u00e1n","year":"2017","unstructured":"Pih\u00e1n P, Carreras-Sureda A, Hetz C. BCL-2 family: integrating stress responses at the ER to control cell demise. Cell Death Differ. 2017;24(9):1478\u201387.","journal-title":"Cell Death Differ"},{"issue":"5","key":"7967_CR78","doi-asserted-by":"publisher","first-page":"E582","DOI":"10.1073\/pnas.1318114111","volume":"111","author":"S Sun","year":"2014","unstructured":"Sun S, Shi G, Han X, Francisco AB, Ji Y, Mendon\u00e7a N, Liu X, Locasale JW, Simpson KW, Duhamel GE, et al. Sel1L is indispensable for mammalian endoplasmic reticulum-associated degradation, endoplasmic reticulum homeostasis, and survival. Proc Natl Acad Sci U S A. 2014;111(5):E582\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"7967_CR79","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.celrep.2019.03.047","volume":"27","author":"G MacLeod","year":"2019","unstructured":"MacLeod G, Bozek DA, Rajakulendran N, Monteiro V, Ahmadi M, Steinhart Z, Kushida MM, Yu H, Coutinho FJ, Cavalli FMG, et al. Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. Cell Rep. 2019;27(3):971\u2013986.e979.","journal-title":"Cell Rep"},{"issue":"6","key":"7967_CR80","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/gut.2010.226092","volume":"60","author":"A Neesse","year":"2011","unstructured":"Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60(6):861\u20138.","journal-title":"Gut"},{"issue":"18","key":"7967_CR81","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-15-2522","volume":"22","author":"B Lamothe","year":"2016","unstructured":"Lamothe B, Wierda WG, Keating MJ, Gandhi V. Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing Proapoptotic and endoplasmic reticulum stress responses. Clin Cancer Res. 2016;22(18):4712\u201326.","journal-title":"Clin Cancer Res"},{"key":"7967_CR82","doi-asserted-by":"crossref","unstructured":"Pommier A, Anaparthy N, Memos N, Kelley ZL, Gouronnec A, Yan R, Auffray C, Albrengues J, Egeblad M, Iacobuzio-Donahue CA, et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science (New York, NY). 2018;360(6394):eaao4908.","DOI":"10.1126\/science.aao4908"},{"issue":"9","key":"7967_CR83","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrc3800","volume":"14","author":"M Wang","year":"2014","unstructured":"Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 2014;14(9):581\u201397.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"7967_CR84","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.cell.2009.07.017","volume":"138","author":"D Han","year":"2009","unstructured":"Han D, Lerner AG, Vande Walle L, Upton JP, Xu W, Hagen A, Backes BJ, Oakes SA, Papa FR. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell. 2009;138(3):562\u201375.","journal-title":"Cell"},{"issue":"5453","key":"7967_CR85","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1126\/science.287.5453.664","volume":"287","author":"F Urano","year":"2000","unstructured":"Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. 2000;287(5453):664\u20136.","journal-title":"Science"},{"issue":"16","key":"7967_CR86","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.1093\/nar\/gkt563","volume":"41","author":"W B'Chir","year":"2013","unstructured":"B'Chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y, Parry L, Stepien G, Fafournoux P, Bruhat A. The eIF2\u03b1\/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res. 2013;41(16):7683\u201399.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"7967_CR87","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tibs.2015.01.002","volume":"40","author":"D Senft","year":"2015","unstructured":"Senft D, Ronai ZA. UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. Trends Biochem Sci. 2015;40(3):141\u20138.","journal-title":"Trends Biochem Sci"},{"key":"7967_CR88","doi-asserted-by":"crossref","unstructured":"Bhardwaj M, Leli NM, Koumenis C, Amaravadi RK. Regulation of autophagy by canonical and non-canonical ER stress responses. Semin Cancer Biol. 2020;66:116\u201328.","DOI":"10.1016\/j.semcancer.2019.11.007"},{"issue":"10","key":"7967_CR89","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2174\/092986709787846578","volume":"16","author":"LK Sharma","year":"2009","unstructured":"Sharma LK, Lu J, Bai Y. Mitochondrial respiratory complex I: structure, function and implication in human diseases. Curr Med Chem. 2009;16(10):1266\u201377.","journal-title":"Curr Med Chem"},{"issue":"5","key":"7967_CR90","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbabio.2012.10.015","volume":"1827","author":"K Kluckova","year":"2013","unstructured":"Kluckova K, Bezawork-Geleta A, Rohlena J, Dong L, Neuzil J. Mitochondrial complex II, a novel target for anti-cancer agents. Biochim Biophys Acta. 2013;1827(5):552\u201364.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"7967_CR91","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1091\/mbc.e11-09-0772","volume":"23","author":"AD Sheftel","year":"2012","unstructured":"Sheftel AD, Wilbrecht C, Stehling O, Niggemeyer B, Els\u00e4sser HP, M\u00fchlenhoff U, Lill R. The human mitochondrial ISCA1, ISCA2, and IBA57 proteins are required for [4Fe-4S] protein maturation. Mol Biol Cell. 2012;23(7):1157\u201366.","journal-title":"Mol Biol Cell"},{"key":"7967_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","volume":"688","author":"CR Gault","year":"2010","unstructured":"Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1\u201323.","journal-title":"Adv Exp Med Biol"},{"key":"7967_CR93","doi-asserted-by":"crossref","unstructured":"van der Hoeven D, Cho KJ, Zhou Y, Ma X, Chen W, Naji A, Montufar-Solis D, Zuo Y, Kovar SE, Levental KR, et al. Sphingomyelin Metabolism Is a Regulator of K-Ras Function. Mol Cell Biol. 2018;38(3):e00373\u201317.","DOI":"10.1128\/MCB.00373-17"},{"issue":"19","key":"7967_CR94","doi-asserted-by":"publisher","first-page":"13005","DOI":"10.1074\/jbc.C600012200","volume":"281","author":"MH Yoo","year":"2006","unstructured":"Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem. 2006;281(19):13005\u20138.","journal-title":"J Biol Chem"},{"issue":"6","key":"7967_CR95","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.celrep.2016.07.009","volume":"16","author":"MS Padanad","year":"2016","unstructured":"Padanad MS, Konstantinidou G, Venkateswaran N, Melegari M, Rindhe S, Mitsche M, Yang C, Batten K, Huffman KE, Liu J, et al. Fatty acid oxidation mediated by acyl-CoA Synthetase long chain 3 is required for mutant KRAS lung tumorigenesis. Cell Rep. 2016;16(6):1614\u201328.","journal-title":"Cell Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07967-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-07967-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07967-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T12:20:58Z","timestamp":1697977258000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-07967-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,6]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7967"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-07967-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,6]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is not needed as no patient data are included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}